Substituted methyl acridone-carboxylate derivatives as CD1/CD2 dual-targeting HDAC6 inhibitors to ameliorate the pathological phenotype of Alzheimer's disease

Retinoic acid receptor is a novel therapeutic target for postoperative cognitive dysfunction

10.3390/pharmaceutics15092311 · doi-reference

The Y-maze for assessment of spatial working and reference memory in mice

10.1007/978-1-4939-8994-2_10 · doi-reference

Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease

10.1093/brain/awz364 · doi-reference

PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain

10.1126/scitranslmed.aba7394 · doi-reference

Fascaplysin derivatives are potent multitarget agents against Alzheimer's disease: in vitro and in vivo evidence

10.1021/acschemneuro.9b00503 · doi-reference

Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation

10.1021/ar8000475 · doi-reference

iClick-Mediated Au(I) functionalization of polystyrene: lighting up polystyrene with phosphorescence

10.1021/acsapm.4c03897 · doi-reference

MCPB.py: a python based metal center parameter builder

10.1021/acs.jcim.5b00674 · doi-reference

Zinc cofactor in human histone deacetylase 8: requirement for function and opportunity for drug discovery

10.1016/j.ijbiomac.2025.149851 · doi-reference

PRODIGY: a web server for predicting the binding affinity of protein-protein complexes

10.1093/bioinformatics/btw514 · doi-reference

Analysing protein complexes in plant science: insights and limitation with AlphaFold 3

10.1186/s40529-025-00462-2 · doi-reference

Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: structure, function and design

10.1016/j.bioorg.2023.106622 · doi-reference

NF-κB in immunobiology

10.1038/cr.2011.13 · doi-reference

The role of HDAC6 in Alzheimer's disease

10.3233/jad-2012-120727 · doi-reference

Microglia facilitate loss of perineuronal nets in the Alzheimer's disease brain

10.1016/j.ebiom.2020.102919 · doi-reference

Therapeutic potential of dual HDAC6/SIRT2 inhibition in Alzheimer's disease

10.1016/j.ejmech.2025.117733 · doi-reference

In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation

10.1093/emboj/cdf682 · doi-reference

Target identification using drug affinity responsive target stability (DARTS)

10.1073/pnas.0910040106 · doi-reference

Synthesis and evaluation of novel N-arylamide-quinoline derivatives as HDAC isoform-selective inhibitors: in vitro and in vivo anticancer efficacy and pharmacokinetic studies

10.1016/j.bioorg.2026.109877 · doi-reference

Synthesis and anticancer research of n‐(2-aminophenyl)benzamide acridine derivatives as dual topoisomerase I and isoform-selective HDAC inhibitors

10.1002/slct.202001880 · doi-reference

Histone deacetylase 10 structure and molecular function as a polyamine deacetylase

10.1038/ncomms15368 · doi-reference

Discovery of novel polysubstituted N-alkyl acridone analogues as histone deacetylase isoform-selective inhibitors for cancer therapy

10.1080/14756366.2023.2206581 · doi-reference

HDAC6 regulates BACE1 stability and NLRP3 inflammasome activation in Alzheimer's disease

10.1093/brain/awag089 · doi-reference

Histone deacetylase 6 structure and molecular basis of catalysis and inhibition

10.1038/nchembio.2134 · doi-reference

Small molecules targeting HDAC6 for cancer treatment: current progress and novel strategies

10.1016/j.biopha.2024.117218 · doi-reference

Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A

10.1021/ja102758v · doi-reference

HDAC6 as privileged target in drug discovery: a perspective

10.1016/j.phrs.2020.105274 · doi-reference

Discovery of HDAC6-selective inhibitor NN-390 with in vitro efficacy in group 3 medulloblastoma

10.1021/acs.jmedchem.1c01585 · doi-reference

Characterization of the two catalytic domains in histone deacetylase 6

10.1016/j.bbrc.2005.12.144 · doi-reference

An acetylation site in the middle domain of Hsp90 regulates chaperone function

10.1016/j.molcel.2006.12.008 · doi-reference

TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90

10.1016/s1097-2765(02)00450-1 · doi-reference

Protopine promotes the proteasomal degradation of pathological tau in Alzheimer'S disease models via HDAC6 inhibition

10.1016/j.phymed.2021.153887 · doi-reference

Inhibition of histone deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer'S disease: a review (2010-2020)

10.1016/j.ejmech.2021.113874 · doi-reference

HDAC6 in diseases of cognition and of neurons

10.3390/cells10010012 · doi-reference

Alzheimer's disease: from immunotherapy to immunoprevention

10.1016/j.cell.2023.08.021 · doi-reference

Pathogenesis of Alzheimer's disease

10.3390/ijms24010107 · doi-reference

Alzheimer's disease

10.1136/bmj.b158 · doi-reference